Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-on Biologics Get Modest Savings Score From CBO, Giving Legislation No Push

This article was originally published in The Pink Sheet Daily

Executive Summary

Congressional Budget Office projects follow-on products could capture 35 percent of market with 40 percent lower price tag.

You may also be interested in...



BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?

Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up

BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?

Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up

Follow-On Biologics Coding Tweaks Could Raise Savings By 30% – CBO

Giving a follow-on biologic the same reimbursement code as its brand name counterpart would increase the savings from FOBs by 30 percent for the federal government's mandatory health care programs, the Congressional Budget Office estimates

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel